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Abstract
Background: Modulation of the expression of retinoic acid receptors (RAR) α  and γ  in adult rat
prostate by testosterone (T) suggests that RAR signaling events might mediate some of the
androgen effects on prostate cells.
Method: In this study, we examined the interactions between T and retinoic acid (RA) in cell
growth of human prostate carcinoma cells, LNCaP, and their relationship with the expression of
RAR and epidermal growth factor receptor (EGF-R).
Results: Both T and RA, when administered alone, stimulated 3H-thymidine incorporation in
LNCaP cells in a dose-dependent manner; the effect of each agent was reciprocally attenuated by
the other agent. Testosterone treatment of LNCaP cells also resulted in dose dependent, biphasic
increases in RAR α  and γ  mRNAs; increases paralleled that of 3H-thymidine incorporation and
were attenuated by the presence of 100 nM RA. These results suggest a link between RAR signaling
and the effect of T on LNCaP cell growth. Gel electrophoretic mobility shift assays revealed the
presence of putative androgen responsive element (ARE) in the promoter region of RAR α  gene,
suggesting that a direct AR-DNA interaction might mediate the effects of T on RAR α  gene.
Furthermore, treatment of LNCaP cells with 20 nM T resulted in an increase in EGF-R. In contrast,
EGF-R was suppressed by 100 nM RA that also suppressed the effect of T.
Conclusions: Current results demonstrate interactions between T and RA in the expression of
RARs and cell growth in LNCaP cells. The presence of putative ARE in the promoter of the RAR
α  gene suggests that AR-DNA interaction might mediate the effects of T on RAR α  gene. The
opposite effects of T and RA on the expression of RAR and EGF-R suggest that signal events of
these receptors might be involved in the interaction between T and RA in the control of LNCaP
cell growth.
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Background
Prostate cancer is one of the major diseases that pose seri-
ous health problems for aging men [1]. It is generally be-
lieved that androgen has a significant role in the
development and progress of this disease [2]. Changes in
the growth response of cancer cells to androgen ablation
and anti-androgen during the progress of the disease [3–
6] suggest that multiple androgen-related signaling events
are involved in neoplasia and disease progression. It has
also been documented that prostate epithelial cells exhib-
ited squamous metaplastic phenotype during vitamin A
deficiency [7], and prostate cell carcinogenesis could be
prevented by retinoic acid (RA) and its analogs in vitro [8–
10]. These findings suggest that retinoid-dependent cellu-
lar events were involved in tumorigenic transformation of
prostate epithelial cells.
Retinoic acid receptors (RARs) and retinoid X receptors
(RXRs) are nuclear transcription factors that mediate the
action of retinoids [11,12]. We have demonstrated that in
the rat, castration resulted in an increase in mRNAs for
RAR α  and γ  in the prostate; such effects were prevented by
T replacement [13]. We also demonstrated that the levels
of mRNAs for RAR α  and γ  in non-tumorigenic rat epithe-
lial cells (NRP152) were down-regulated, whereas those
in tumorigenic cells (NRP154) were unaffected or up-reg-
ulated following T treatment [14]. In addition, RAR α  was
over-expressed in tumorigenic NRP154 cells. These find-
ings suggest that tumorigenic transformation and perhaps
neoplasia of prostate epithelial cells are associated with
abnormal expression and androgen regulation of RARs.
Androgen exerts its biologic effects by binding to and ac-
tivation of androgen receptor (AR) that trans-activates tar-
get genes through androgen responsive element (ARE) in
the promoter of target genes [15]. In human breast cancer
cells the effectiveness of retinoids in cell growth suppres-
sion was dictated by the presence of RAR [16]. Estrogen
regulation of the expression of RAR α  was mediated by in-
teractions between estrogen receptor (ER) and estrogen re-
sponsive element (ERE) in the promoter of RAR α  gene
[17]. Because the DNA binding domains of steroid recep-
tors including AR and ER are highly homologous, we pos-
tulated that similar mechanisms might also mediate the
effect of androgen on RAR genes in prostate cells.
The current experiments investigate the effects of T and its
interaction with RA on cell growth and the expression of
RARs in human prostate cancer cells, LNCaP. Further-
more, we present evidence to suggest that T may affect the
expression of RAR α  gene through direct interaction be-
tween AR and putative ARE in the promoter of RAR α
gene. Because EGF and its receptor (EGF-R) are involved
in prostate cell growth, and their expression can be mod-
ulated by androgen and RA [18–20], we also examined
the interaction of T and RA on the expression of EGF-R.
Materials and methods
Cell culture
Human prostate carcinoma cells, LNCaP (ATCC, Rock-
ville, MD), were maintained and propagated in T25 flasks
in RPMI 1640 media (GIBCO-BRL, Gaithersburg, MD)
supplemented with 10% FCS (Gemini Bio-Products, Cal-
abasas, CA), 2 mM glutamine, Fungizone (1 µg/ml) and
penicillin (200 unit/ml)/ streptomycin (200 µg/ml) (re-
ferred as complete medium) in a 37°C humidified 5%
CO2 incubator.
3H-thymidine incorporation
Sub-confluent (80–90%) LNCaP cells propagated in T25
flasks were washed with 5 ml of plain RPMI 1640 medium
and trypsinized with 5 ml trypsin/EDTA solution (GIB-
CO-BRL, Gaithersburg, MD). The cells were then seeded
onto the 12-well plates (2–5 ×  104 cells/well) in 4 ml
complete media. Two days later, the cells were well at-
tached and covered 40–50% of the surface area. At this
time the FCS in the medium was replaced by charcoal-
stripped FCS (cFCS, Gemini Bio-Products), and various
concentrations of T and/or all trans retinoic acid (RA)
were added in triplicates. Three days later, the medium
was removed and the cells were incubated in 1 ml plain
medium containing 3H-thymidine (0.5 µCi/ml) for an ad-
ditional 4 h. After washing twice with 3 ml of plain medi-
um, the cells were lysed with 0.2 ml of lysis buffer
containing 0.1 M NaCl, 0.01 M EDTA, 0.3 M Tris-HCl (pH
8.0), 0.2 M sucrose and 0.5% SDS. DNA was extracted
with phenol/chloroform/isoamyl alcohol (25:24:1) solu-
tion and precipitated with an equal volume of isopropa-
nol. After washing with 70% ethanol, DNA was
subsequently precipitated by centrifugation. The specific
activity of 3H-thymidine was then determined and ex-
pressed as cpm/µg DNA.
Northern blot analysis of RAR mRNA
To determine the effects of T on RAR mRNA expression,
LNCaP cells were propagated in 20 ml complete medium
in T175 flasks, with medium change every 4th day, until
the monolayers reached >90% confluence (usually 8–10
days after seeding). The FCS in the medium was then re-
placed by cFCS. 48 h later, various concentrations of Test-
erone were added in the absence or presence of 100 nM
RA. The cells were harvested 6 h later. This time was select-
ed based on results of preliminary experiments (data not
shown).
Detailed procedures for isolation of total RNA, enrich-
ment of poly (A)+ RNA by oligo-dT cellulose chromatog-
raphy and electrophoresis and Northern blotting of RNA
have been described previously [13]. The cDNA probes ofBMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/16
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mouse RAR α  and RAR γ  [21,22] were isolated by agarose
electrophoresis after appropriate endonucleases digestion
and were radio-labeled with 32P-dCTP, using random
priming kit (Boehringer-Mannheim, Indianapolis, IN).
The blots were pre-hybridized in a solution containing 6-
strength SSC (150 mM NaCl, 15 mM Na-citrate, pH 7.0),
0.5% SDS, 50% formamide, and 100 mg/ml denatured
sperm DNA at 42°C for 2–4 h, and were hybridized over-
night in the same buffer containing approximately 106
cpm/ml of radiolabeled cDNA probe. The membranes
were washed in 1×  SSC solution containing 0.1% SDS at
68°C for 20–30 min, followed by several changes in 0.2-
strength SSC and 0.1% SDS at 68°C for 2–4 h. The radio-
autographs were developed after they were exposes to Ko-
dak (Eastman Kodak, Rochster, NY) XAR-5 film for 2–10
days using an intensifying screen. The membranes were
subsequently stripped and rehybridized with 32P labeled
cDNA for 18S ribosomal RNA. The relative abundance of
different transcripts (RAR α , 3.4 and 2.7 Kb; RAR γ , 3.4
Kb) were scanned, and area under the curve was estimated
by densitometry. The result of each sample was normal-
ized against that of the 18S ribosomal RNA in each sam-
ple. The average ratio between the mRNA and the 18 S
ribosomal RNA of untreated control cells were considered
100 %, and the results for individual experimental sam-
ples in each blot were expressed as a percentage of this av-
erage.
Electrophoretic mobility shift assays (EMSA)
The oligo corresponding to nucleotides -100 to -59 of RAR
α  promoter (antisense strand: 5'
TCGACTGCCCGCCCACCGACCAATCACCAGTCAG-
GGGCGGATCTAC 3'; sense strand: 5'
CCGGGTAGATCCGCCCCTGACTGGTGATTGGTCGGT-
GGGCGGGCAG 3') [17] was synthesized by the New Jer-
sey Medical School Molecular Resource Facility. The oligo
probes were radiolabeled using the Klenow fragment of
DNA polymerase and 32P-dATP. The binding between
DNA and AR was determined by gel electrophoretic mo-
bility shift assay. Purified human AR protein over-ex-
pressed in the baculovirus [23] or nuclear protein extracts
of LNCaP cells were incubated with 2 µg polydeoxynosin-
ic-deoxycytidylic acid and 1×  binding buffer (10 mM
HEPES, pH 7.5, 1 mM mercaptoethanol, 10% glycerol
and 50 mM KCl) on ice for 30–60 min. After addition of
32P-labeled probe (1 ng/reaction), the mixture was incu-
bated for an additional 30 min on ice. Non-specific com-
petitor (5' CGCCC GGGGT CCTCA GCG 3') or excess
unlabeled specific probe were added 10–15 min before
adding the radioactive probe. To super-shift the AR-DNA
complex, AR protein was incubated with polyclonal AR-
specific antibody (CW2) [24] prior to the addition of the
radioactive oligo probe. The reaction mixtures were elec-
trophoresed on a 6 % non-denaturing polyacrylamide gel
(acrylamide: bisacrylamide, 30: 0.8) containing 5 % glyc-
erol at 180 V in TAE buffer (1 mM DEAE, 3.3 mM sodium
acetate and 6.7 mM Tris, pH 7.5). The gels were dried at
60°C and DNA/protein binding was visualized by radio-
autography. The same experiments were repeated at least
3 times.
Measurement of EGF receptor
LNCaP cells (approximately 90% confluence) propagated
in T75 flasks were treated with T (20 nM), RA (100 nM) or
a combination of both in medium containing cFCS as de-
scribed above for 24h. The cells were subsequently har-
vested for the isolation of cell membranes by the method
described by Wang et al. [25].
Ligand-binding assay
Duplicates of membrane preparations equivalent to 0.1
mg protein were incubated with 125I-EGF (50 or 100 ng;
Amersham Life Sciences, Arlington Heights, IL) in 200 µl
reaction buffer (5 mM Tris-HCl, pH 7.0, 125 mM sucrose,
75 mM NaCl, 0.5 mM Ca2+ and 0.5% BSA) at 25°C for 60
min. Non-specific binding was obtained by adding 100×
non-radioactive EGF (Sigma Biochemicals, St. Louis,
MO). The reaction was stopped by addition of 1 ml ice
cold washing buffer (5 mM Tris-HCl and 0.5% BSA, pH
7.0), and membrane bound (125I)EGF was precipitated
immediately by centrifugation (14,000 rpm ×  4 min) at
4°C. The pellets were washed with 1 ml washing buffer
and re-pelleted. Specific binding was obtained by sub-
tracting non-specific binding (in the presence of a 100-
fold excess unlabeled EGF) from total binding. The results
were expressed as fmol/mg protein.
Western blots analysis of EGF-R
The cell pellets were re-suspended in 1 ml PBS, lysed by
boiling and stored as 0.1 ml aliquots at -70°C. For West-
ern blot analysis, 15 µl of samples containing 20 µg pro-
tein were mixed with equal volume of 2 ×  loading buffer
(1X = 125 mM TRIS-HCl, pH 6.8; 2% SDS, 5% glycerol,
0.003% bromphenol blue and 1% 1-mercaptoethanol),
and boiled for 5 min. Fifteen (15) µl of the samples were
electrophoresed on a 7.5% SDS-polyacrylamide mini-gel
for 1 h at 150 V. The proteins were transferred to a PVDF
membrane (Amersham Life Sciences, Arlington Heights,
IL) using a Mini Trans-blot Cell (Bio Rad Laboratories,
Hercules, CA) at 50 mA. The membranes were blocked
overnight at 4°C in TBST (10 mM Tris-HCl, 150 mM Na-
Cl, 0.05% Tween; pH 8.0) containing 3% fat free dry milk.
Thereafter, the membrane was incubated with a mono-
clonal anti-human EGF-R antibody (Oncogene Research
Products, Cambridge, MA) diluted 1:10 in TBST at room
temperature for 2 h. After washing in TBST for 1 h, the
membrane was incubated with anti mouse IgG/peroxi-
dase conjugate (1:8,000 in TBST) for 1 h at room temper-
ature. The signal was enhanced by ECL Western blot
detection kit (Amersham Life Sciences, Arlington Heights,BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/16
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IL) and exposed to Kodak X-OMAT film. The identical ex-
periments were repeated 3 times.
Statistics
Analysis of variance (ANOVA) was used to detect the
dose-effect of T and/or RA, using the JMP statistical soft-
ware package (SAS Institute, Cary, NC). Subsequently,
Dunnetts multiple-range test was used to compare the
means among groups. Unpaired Student's t test was used
to determine the effect of RA on the RAR mRNA responses
to T.
Results
3H-thymidine incorporation
Treatment of LNCaP cells with 0.02–2000 nM T alone for
3 days resulted in dose-dependent, biphasic stimulation
of  3H-thymidine incorporation (p < 0.05; Figure 1A).
While effects of 0.02 nM T was abolished by 1 and 100 nM
RA (p < 0.05), the effect of higher doses of T were sup-
pressed by all doses of RA used (p < 0.05). The extent of
suppression depended on the doses of both T and RA.
Specifically,  3H-thymidine uptake in cells treated with
20–2000 nM T was suppressed by the presence of 1 nM RA
to an extent that was significantly lower than untreated
controls (p < 0.05). Similarly, treatment of LNCaP cells
with 0.01–10 nM RA alone resulted in 50–70% stimula-
tion of 3H-thymidine uptake (p < 0.05, Figure 1B); these
effects were suppressed by concomitant presence of 0.02–
200 nM T (p < 0.05). Such effects became less pronounced
when higher doses of RA were used. Combination of 100
and 1000 nM RA with 0.02 nM T resulted in lower 3H-thy-
midine uptake than those cells treated with RA alone (p <
0.05).
RAR α  and γ  mRNA
Treatment of LNCaP cells with T alone for 6 h resulted in
dose-dependent, biphasic increases in levels of RAR α  and
γ  mRNA transcripts, with the maximal effect of 2–20 nM
(P < 0.05; Figure 2). When the cells were treated with T in
the presence of 100 nM RA, the RAR α  and γ  mRNAs in
LNCaP cells were suppressed in a dose dependent manner
(P < 0.05, Figure 3). The 4.0 kb RAR α  mRNA was not af-
fected by these treatments.
Figure 1
Dose effect of testosterone (A) and retinoic acid (B) on 3H-
thymidine incorporation in LNCaP cells
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Figure 2
Dose effects of testosterone on the level of mRNA for RAR
α  and γ  in LNCaP cells in the absence of retinoic acid
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Electrophoretic mobility shift assay (EMSA)
Incubation of AR protein with the 32P-labeled oligo probe
of RAR α  promoter resulted in a protein-DNA complex af-
ter EMSA (Figure 4A); radioactivity of the complex was
displaced by unlabeled oligo probe, but not by oligo
probe of unrelated sequences. This complex was not
present when the probe was incubated with BSA. Incuba-
tion of nuclear extracts of LNCaP cells with the 32P-oligo
probe also resulted in a complex that migrated to the same
distance as that achieved by AR-32P-oligo probe complex
(Figure 4B). The specificity of such complex was demon-
strated by displacement of radioactivity with unlabeled
specific oligo probe. Incubation of AR protein with anti-
AR polyclonal antibody (CW2) prior to the addition of
32P-labeled oligo probe resulted in super-shifting of the
protein-DNA complex (Figure 4C).
Interaction of RA and T on EGF-R
Figure 5 shows that treatment of LNCaP cells with RA
(100 nM) alone for 24 h resulted in > 20% decrease in the
binding of 125I-EGF and membrane proteins (P < 0.05).
On the other hand, binding of 125I-EGF was stimulated by
75% in cells treated with 20 nM T (P < 0.05), but this ef-
fect was attenuated by the presence of RA. Western blot
analysis revealed a similar pattern of change in the 170 kd
EGF-R protein.
Discussion
Androgen is essential for normal prostate function, but
has also been implicated in the pathogenesis and neopla-
sia of prostate cancer [1,2,26]. On the other hand, retin-
oid is essential for normal prostate function [7,27,28] and
exhibits anti-proliferative and chemopreventive efficacy
in experimental prostate carcinoma [8–10]. The dose-de-
pendent stimulation of 3H-thymidine incorporation in
LNCaP cells by T and RA when administered alone, and
reciprocal suppression of such effects by each other, are
consistent with previous findings [29–32]. These results
illustrate interactions between androgen and retinoid in
the control of LNCaP cell growth. A correlation between
dose effect of T on 3H-thymidine incorporation and that
on RAR α  and γ  mRNA levels further suggests that RAR sig-
naling events might be involved in such interaction. Stim-
ulation of LNCaP cell growth by RAR analog [33] and
over-expression of RAR α  in tumorigenic rat prostate epi-
thelial cells [14] support the above notion.
Modulation of the expression of EGF and its receptor
(EGF-R) in prostate cells by androgen [18,19,26], and
over-expression of EGF-R during the advanced stages of
Figure 3
Dose effects of testosterone on the level of mRNA for RAR
α  and γ  in LNCaP cells in the presence of 100 nM retinoic
acid
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prostate cancer [34], imply that EGF/EGF-R signaling
events might be involved in neoplasia and perhaps pro-
gression of prostate cancer. An increase in EGF-R in
LNCaP cells after treatment with growth-stimulating dose
of T is consistent with this postulate. Suppression of EGF-
R in LNCaP cells after treatment with a dose of RA that
also attenuated the stimulating effect of T on EGF-R, fur-
ther suggest that EGF-R signaling might have a role in the
interaction between T and RA on LNCaP cell growth. In
this regard, RA was reported to blunt the growth response
of LNCaP cells to EGF [31]. These investigators also re-
ported increases and decreases in LNCaP cells in S-phase
after exposure to growth stimulating and anti-proliferative
doses of RA, respectively. Treatment of LNCaP cells with
an RXR agonist also caused an increase in G1 cells and a
decrease in S phase cells [33], suggesting that cell cycle ki-
netics are involved in the effects of RA/RAR signaling.
Binding between AR and nucleotide sequences of the pro-
moter of the RAR α  gene and that such protein-DNA com-
plex was super-shifted in the presence of anti-AR serum
suggest the presence of ARE in RAR α  gene. This notion is
supported by the presence, within the oligo probe, of nu-
cleotides sequences 5'AGATCC 3' (n-98 to -93) and
5'ACTGGT 3' (n-85 to -80) which are identical or comple-
mentary to half of the palindromic ARE motif of prostat-
ien C3 subunit gene (5'AGTACG 3') [35] and that of PSA
promoter (5' AGTGCT 3') [20], respectively. Binding be-
tween LNCaP cell nuclear extract and oligo probe of RAR
α  promoter thus suggests that AR-ARE interaction might
mediate the effects of T on the expression of RAR α  in
LNCaP cells. A similar mechanism may also pertain for
the effects of T on RAR γ  since the DNA binding domains
are highly homologous among RARs. In addition, se-
quences in other segments of the RAR α  promoter includ-
ing 5' GGGACA 3' (n -46 to -41) and 5' TCTGCT 3' (n -25
to -20) were similar or complementary to that of half site
of the up-stream ARE (GGAACAtatTGTATC) and promot-
er ARE (AGAACAgcaAGTGCT) of PSA gene [20], respec-
tively. Oligo probes containing these sequences also
interacted with AR protein (data not shown). These results
further suggest possible presence of multiple AREs in the
RAR α  gene. Functional importance of multiple AREs in
androgen effects has been demonstrated in PSA gene [20].
Stimulation of RAR α  and γ  mRNA in LNCaP cells by T dif-
fered from that in normal rat prostate and non-tumori-
genic rat prostate epithelial cells (NRP-152), but was
comparable to that in tumorigenic rat prostate epithelial
cells (NRP-154)[13,14]. In cervical carcinoma cells, the
RAR β  gene was abnormally down-regulated by RA [36].
In ER positive human breast cancer cells, RAR α  mRNA
was also up-regulated by estrogen [16]. Thus, T stimula-
tion of RAR mRNAs in LNCaP cells could be related to the
pathologic state of the cells. LNCaP cells contain high lev-
els of functional AR with mutated ligand binding domain
and exhibit aberrant cellular responses to androgen
[5,37,38]. The mutated AR when interact with the ARE of
the RAR-α  gene, may trans-activate the gene in an abnor-
mal fashion resulting in increases in its mRNA.
In summary, current results demonstrate interactions be-
tween T and RA in the expression of RAR α  and γ  and EGF-
R, as well as cell growth in LNCaP cells. These results sug-
gest that RAR and EGF-R signaling events might be in-
volved in the effects of RA and T on LNCaP cell growth.
Moreover, EMSA demonstrated the presence of putative
ARE on RAR α  promoter, suggesting that AR (protein)-
DNA interaction might be involved in the effects of T on
RAR genes. While the importance of these in vitro findings
for prostate cell patho-physiology in vivo must be inter-
preted with caution, current results nevertheless provide a
molecular basis for the interaction between androgen and
retinoid in LNCaP cells. Further understanding the down-
stream signaling events in such interaction will provide
new insights into the mechanisms underlying normal and
pathologic growth of prostate cells, and will facilitate the
Figure 5
The interaction of testosterone (20 nM) and retinoic acid
(100 nM) on EGF-receptor in LNCaP cells. Panel A, Ligand
binding; Panel B, Western blot.
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use of retinoid analogs in the prevention or treatment of
such diseases as prostate cancer.
Competing interests
None declared.
Authors' contributions
Author #1 has been responsible for most of the experi-
ments including 3H-thymidine incorporation, Northern
blotting, electrophoretic mobility shift assay (EMSA) and
some cell culture experiments. Author #2 was responsible
for all EGF-R experiments. Author #3 has contributed pu-
rified androgen receptor and its antibody for EMSA, as
well as consultation in the design of the experiments. Au-
thor #4 has provided suggestions for the experiments and
potential clinical relevance of the findings. Author #5 has
been responsible for the progress of the experiments, par-
ticipated in cell culture experiments and preparation of
the manuscript
Acknowledgments
We thank Professor P. Chambon for the generous gift of RAR cDNAs and 
Ms. Faith Knabe for critical editorial review and suggestions. This study is 
supported in part by C. R. Bard Endowed Fund. Dr. Dr. Hosea F. S. Huang 
is a recipient of a grant from the Department of Veterans Affairs Rehabili-
tation Research and Development Service. Frank Richter is a recipient of a 
training grant (Ri 773/2-1) from Deutsche Forschungsgemeinschaft (DFG), 
Germany.
References
1. Boyle MP, Napalkov P: Incidence of prostate cancer will double
by year 2030: the argument for. Eur. Urol. 1996, 29(Supple.
2):3-9
2. Bostwick DG, Sole Balcells F, Cooner WH, Denis L, Fang-Liu G, Jones
GW, Khoury S, Kotake T, DeMatteis A, Pagano F, Scardino PT, Mur-
phy GP: Benign prostatic hyperplasia (BPH) and cancer of the
prostate. In: Proceedings of the International Consultation on Benign Pro-
static Hyperplasia (BPH)  (Edited by: Cockett ATK, Aso Y, Chatelain C,
Denis L, Griffiths K, Khoury S, Murphy GP) Paris 1991, 139-159
3. Whitmore WF Jr: The natural history of prostate cancer. Cancer
1973, 32:1104-1112
4. Thalmann GN, Anezis PE, Chang SM, Zhau HE, Kim E, Hopwood VL,
Pathak S, Von Eshenbach AC, Chung LWK: Androgen-independ-
ent cancer progression and bone metastasis of human pros-
tate cancer. Cancer Res. 1994, 54:2577-2581
5. Kokontis J, Takakura K, Hay N, Liao S: Increased androgen recep-
tor activity and latered c-myc expression in prostate cancer
cells after long-term androgen deprivation. Cancer Res. 1994,
54:1566-1573
6. Zhau HY, Chang SM, Chen BQ, Wang Y, Zhang H, Kao C, Sany QA,
Pathak SJ, Chung LWK: Androgen-repressed phenotype in hu-
man prostate cancer. Proc. Natl. Acad. Sci. USA 1996, 93:15152-
15157
7. Thompson JN, Howell JM, Pitt GAJ: Vitamin A and reproduction
in rats. Proc. Royal Soc. B 1964, 159:510-534
8. Pienta KJ, Nguyen NM, Lehr JE: Treatment of prostate cancer in
the rat with the synthetic retinoid fenretinide.  Cancer Res.
1993, 53:224-226
9. Pollard M, Luckert PH, Sporn MB: Prevention of primary pros-
tate cancer in Lobund Wistar rats by N-(4-hydroxyphenyl)
retinamide. Cancer Res. 1991, 51:3610-3611
10. Stearns ME, Wang M, Fudge K: Lianzole and 13-cis-retinoic acid
anti-prostatic tumor activity. Cancer Res. 1993, 53:3073-3077
11. Chambon P: The molecular and genetic dissection of the retin-
oic signal pathway. Recent Prog. Horm. Res. 1995, 50:317-332
12. Evans RM: The steroid and thyroid hormone receptor super-
family. Science 1988, 240:889-895
13. Huang HFS, Li MT, VonHagen S, Zhang YF, Irwin RJ: Androgen
modulation of the messenger ribonucleic acid of retinoic
acid receptors in the prostate, seminal vesicles, and kidney
in the rat. Endocrinol. 1997, 138:553-559
14. Richter F, Huang HFS, Li MT, Irwin RJ: Differential regulation of
normal and carcinoma rat prostate epithelial cells by testo-
sterone and reintoic acid. Expression of retinoic acid recep-
tors and epidermal growth factor receptor. Mol. Cell. Endocrinol.
1999, 153:29-38
15. Murtha P, Tindall DJ, Young CYF: Androgen induction of a hu-
man prostate-specific kallikrein, hKLK2: characterization of
an androgen responsive element inthe 5' promoter region of
the gene. Biochem. 1994, 32:6459-6464
16. Roman SD, Ormandy CJ, Manning DL, Blamey RW, Nicholson RI,
Sutherland RI, Clark CL: Estradiol induction of retinoic acid re-
ceptors in human breast cancer cells.  Cancer Res. 1993,
53:5940-5945
17. Rishi A, Shao Z-M, Baumann RG, Li X-S, Shekkh MS, Kimura S, Ba-
shirelahi N, Fontana JA: Estradiol regulation of the human retin-
oic acid receptor a gene in human breast carcinoma cells is
mediated via an imperfect half-palindromic estrogen re-
sponse element and Sp1 motifs. Cancer Res. 1995, 55:4999-5006
18. Traisch AM, Wotiz HH: Prostatic epidermal growth factor re-
ceptors and their regulation by androgen.  Endocrinol. 1987,
121:1461-1467
19. Schuurmans ALG, Bott J, Voorhorst MM, Blankerstein RA, Mulder E:
Regulation of growth and epidermal growth factor receptor
levels of LNCaP prostate tumor cells by different steroids.
Int. J. Cancer 1988, 42:917-922
20. Zhang S, Murtha PE, Young CYF: Defining a functional androgen
receptor responsive element in the 5' far upstream flanking
region of the prostate-specific antigen gene. Biochem. Biophys.
Res. Comm. 1997, 231:784-788
21. Zelent A, Krust A, Petkovich M, Kastner P, Chambon P: Cloning of
murine α  and β  retinoic acid receptors and a novel receptor
predominantly expressed in skin. Nature 1989, 339:714-717
22. Krust A, Kastner P, Petkovich M, Zelent A, Chambon P: A third hu-
man retinoic acid receptor, h-RAR-γ . Proc. Natl. Acad. Sci. USA
1989, 86: 129-134
23. Chang C, Wang C, DeLuca HF, Ross TK, Shih CC: Characteriza-
tion of human androgen receptor overexpressed in the bac-
ulovirus system. Proc. Natl. Acad. Sci. USA 1992, 89:5946-5950
24. Chang CS, Whelan CT, Popovich TC, Kokontis J, Liao ST: Fusion
proteins containing androgen receptor sequences and their
use in the production of poly- and monoclonal anti-androgen
receptor antibodies. Endocrinology 1989, 125:1097-1099
25. Wang SI, Shiverick KT, Ogilvie S, Dunn WA, Raizada MK: Charac-
terizations of epidermal growth factor receptors in astro-
cytic glial and neuronal cells in primary culture. Endocrinol.
1989, 36:
26. Griffiths K, Akaza H, Eaton CL, Etreby ME, Habib F, Lee C, Partin AW,
Coffey DS, Sciarra F, Steiner G, Tenniswood MP: Regulation of
prostate growth. In: Proc. of the Second Internationl Consultation on
Benign Prostatic Hyperplasia (BPH)  (Edited by: Khoury ATK) Paris 1993
27. Wolbach S, Howe PR: Tissue changes following deprivation of
fat-soluble vitamin A. J. Exp. Med. 1942, 42:753-777
28. De Luca LM: Retinoids and their receptors in differentiation,
embryogenesis and neoplasia. FASEB J 1991, 5:2924-2933
29. Young CYF, Montgomery BT, Andrwes PE, Oiu S, Bihartz BL, Tindall
DJ: Hormonal regulation of prostate-specific antigen mes-
senger RNA in human prostatic adenocarcinoma cell line
LNCaP. Cancer Res. 1991, 53:3748-3752
30. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amstel I, Shaw
N, Prins GS, Kozlowski JM: Regulation of proliferation and pro-
duction ofprostate specific antigen in androgen-sensitive
prostatin cancer cells, LNCaP, by dihydrotestosterone. Endo-
crinol. 1995, 136:796-803
31. Fong CJ, Sutkowski DM, Braun EJ, Bauer KD, Sherwood ER, Lee C,
Kozlowski JM: Effect of retinoic acid on the proliferation and
secretroy activity of androgen responsive prostatic carcino-
ma cells. J. Urol. 1993, 149:1190-1194
32. Esquenet M, winnen JV, Heyns W, Verhoeven G: Control of
LNCaP proliferation and differentiation: Actions and inter-
actions of androgens, 1 α , 25-dihydroxycholecalciferol, all-
trans-retinoic acid, 9-cis retinoic acid, and phenylacetate.
Prostate 1996, 28:182-194BMC Cancer 2002, 2 http://www.biomedcentral.com/1471-2407/2/16
Page 8 of 8
(page number not for citation purposes)
33. Blutt SE, Allegretto EA, Pike JW, Weigel NL: 1,25-dihydroxyvita-
min D3 and 9-cis retinoic acid act synergistically to inhibit
the growth of LNCaP prostsate cells and cause accumulation
of cells in G1. Endocrinol. 1997, 138:1491-1497
34. Davies P, Eaton CL: Binding of epidermal growth factor by hu-
man normal, hypertrophic and carcinomatous prostate. Pros-
tate 1989, 14:123-132
35. Ho KC, Marschke KB, Tan J, Power SGA, Wilson EM, French SF: A
complex response element in intron 1 of the androgen-reg-
ulated 20-kDa protein gene displays cell type-dependent an-
drogen receptor specificity. J. Biol. Chrm. 1993, 268:27226-27235
36. Geisen C, Denk C, Gremm B, Baust C, Karger A, Bollag W, Scharz E:
High-level expression of the retinoic acid receptor β  gene in
normal cells of the uterine cervix is regulated by the retinoic
acid receptor α  and is abnormally down-regulated in cervical
carcinoma cells. Cancer Res. 1997, 57:1460-1467
37. Veldschoote J, Berrevoets CA, Ris-Stalphers C, Kuiper GGJM, Jenster
G: The androgen receptor in LNCaP cells contains a muta-
tion in the ligand binding domain which affects steroid bind-
ing characteristics and response to anti-androgen. J. Steroid
Mol. Biochem. 1992, 41:665-669
38. Wilding G, Chen M, Gelman E: Aberrant response in vitro of hor-
mone responsive prostate cancer to anti-androgens. Prostate
1989, 14:103-115
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2407/2/16/prepub
Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMedcentral will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Paul Nurse, Director-General, Imperial Cancer Research Fund
Publish with BMC and your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours - you keep the copyright
editorial@biomedcentral.com
Submit your manuscript here:
http://www.biomedcentral.com/manuscript/
BioMedcentral.com